BACKGROUND: For decades, non-Hodgkin lymphoma (NHL) incidence has been increasing worldwide. NHL risk is strongly increased among HIV-infected people. Our understanding of trends in NHL incidence has been hampered by difficulties in separating HIV-infected NHL cases from general population rates. METHODS: NHL incidence data during 1992-2009 were derived from 10 U.S. SEER cancer registries with information on HIV status at NHL diagnosis. The CDC estimated the number of people living with HIV in the registry areas. The proportion of NHL cases with HIV and NHL rates in the total and the HIV-uninfected populations were estimated. Time trends were assessed with Joinpoint analyses. RESULTS: Of 115,643 NHL cases diagnosed during 1992-2009, 5.9% were HIV-infected. The proportions of NHL cases with HIV were highest for diffuse large B-cell (DLBCL; 7.8%), Burkitt (26.9%), and peripheral T-cell lymphomas (3.2%) with low proportions (≤1.1%) in the other subtypes. NHL rates in the total population increased 0.3% per year during 1992-2009. However, rates of NHL in HIV-uninfected people increased 1.4% per year during 1992-2003, before becoming stable through 2009. Similar trends were observed for DLBCLs and follicular lymphoma in HIV-uninfected people; rates increased 2.7% per year until 2003 and 1.7% per year until 2005, respectively, before stabilizing. CONCLUSIONS: NHL incidence rates in the United States have plateaued over the last 5-10 years, independent of HIV infection. IMPACT: Although the causes of the long-term increase in NHL incidence rates in the United States remain unknown, general population rates of NHL have stabilized since the early 2000s, independent of HIV.
BACKGROUND: For decades, non-Hodgkin lymphoma (NHL) incidence has been increasing worldwide. NHL risk is strongly increased among HIV-infected people. Our understanding of trends in NHL incidence has been hampered by difficulties in separating HIV-infected NHL cases from general population rates. METHODS: NHL incidence data during 1992-2009 were derived from 10 U.S. SEER cancer registries with information on HIV status at NHL diagnosis. The CDC estimated the number of people living with HIV in the registry areas. The proportion of NHL cases with HIV and NHL rates in the total and the HIV-uninfected populations were estimated. Time trends were assessed with Joinpoint analyses. RESULTS: Of 115,643 NHL cases diagnosed during 1992-2009, 5.9% were HIV-infected. The proportions of NHL cases with HIV were highest for diffuse large B-cell (DLBCL; 7.8%), Burkitt (26.9%), and peripheral T-cell lymphomas (3.2%) with low proportions (≤1.1%) in the other subtypes. NHL rates in the total population increased 0.3% per year during 1992-2009. However, rates of NHL in HIV-uninfected people increased 1.4% per year during 1992-2003, before becoming stable through 2009. Similar trends were observed for DLBCLs and follicular lymphoma in HIV-uninfected people; rates increased 2.7% per year until 2003 and 1.7% per year until 2005, respectively, before stabilizing. CONCLUSIONS: NHL incidence rates in the United States have plateaued over the last 5-10 years, independent of HIV infection. IMPACT: Although the causes of the long-term increase in NHL incidence rates in the United States remain unknown, general population rates of NHL have stabilized since the early 2000s, independent of HIV.
Authors: Meredith S Shiels; Ruth M Pfeiffer; Mitchell H Gail; H Irene Hall; Jianmin Li; Anil K Chaturvedi; Kishor Bhatia; Thomas S Uldrick; Robert Yarchoan; James J Goedert; Eric A Engels Journal: J Natl Cancer Inst Date: 2011-04-11 Impact factor: 13.506
Authors: Meredith S Shiels; Ruth M Pfeiffer; H Irene Hall; Jianmin Li; James J Goedert; Lindsay M Morton; Patricia Hartge; Eric A Engels Journal: JAMA Date: 2011-04-13 Impact factor: 56.272
Authors: S A M van de Schans; D E Issa; O Visser; P Nooijen; P C Huijgens; H E Karim-Kos; M L G Janssen-Heijnen; J W W Coebergh Journal: Ann Oncol Date: 2011-04-04 Impact factor: 32.976
Authors: Lindsay M Morton; Sophia S Wang; Wendy Cozen; Martha S Linet; Nilanjan Chatterjee; Scott Davis; Richard K Severson; Joanne S Colt; Mohammad A Vasef; Nathaniel Rothman; Aaron Blair; Leslie Bernstein; Amanda J Cross; Anneclaire J De Roos; Eric A Engels; David W Hein; Deirdre A Hill; Linda E Kelemen; Unhee Lim; Charles F Lynch; Maryjean Schenk; Sholom Wacholder; Mary H Ward; Shelia Hoar Zahm; Stephen J Chanock; James R Cerhan; Patricia Hartge Journal: Blood Date: 2008-09-16 Impact factor: 22.113
Authors: Betsy A Kohler; Elizabeth Ward; Bridget J McCarthy; Maria J Schymura; Lynn A G Ries; Christie Eheman; Ahmedin Jemal; Robert N Anderson; Umed A Ajani; Brenda K Edwards Journal: J Natl Cancer Inst Date: 2011-03-31 Impact factor: 13.506
Authors: Nadia Howlader; Lindsay M Morton; Eric J Feuer; Caroline Besson; Eric A Engels Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-10-15 Impact factor: 4.254
Authors: Hilary A Robbins; Ruth M Pfeiffer; Meredith S Shiels; Jianmin Li; H Irene Hall; Eric A Engels Journal: J Natl Cancer Inst Date: 2015-02-06 Impact factor: 13.506
Authors: S K Barta; M S Samuel; X Xue; D Wang; J Y Lee; N Mounier; J-M Ribera; M Spina; U Tirelli; R Weiss; L Galicier; F Boue; R F Little; K Dunleavy; W H Wilson; C Wyen; S C Remick; L D Kaplan; L Ratner; A Noy; J A Sparano Journal: Ann Oncol Date: 2015-01-28 Impact factor: 32.976
Authors: Elizabeth K Cahoon; Ruth M Pfeiffer; David C Wheeler; Juan Arhancet; Shih-Wen Lin; Bruce H Alexander; Martha S Linet; D Michal Freedman Journal: Int J Cancer Date: 2014-10-13 Impact factor: 7.396
Authors: David J Riedel; Kristen A Stafford; Aparna Vadlamani; Robert R Redfield Journal: AIDS Res Hum Retroviruses Date: 2016-12-13 Impact factor: 2.205
Authors: Chad J Achenbach; Ashley L Buchanan; Stephen R Cole; Lifang Hou; Michael J Mugavero; Heidi M Crane; Richard D Moore; Richard H Haubrich; Satish Gopal; Joseph J Eron; Peter W Hunt; Benigno Rodriguez; Kenneth Mayer; Michael S Saag; Mari M Kitahata Journal: Clin Infect Dis Date: 2014-02-12 Impact factor: 9.079